Cyclophosphamide

Generic Name: Cyclophosphamide

Brand Names: Procytox

Drug Type: Small Molecule

Chemical Formula: C_₇H_₁₅Cl_₂N_₂O_₂P

CAS Number: 50-18-0

Unique Ingredient Identifier: 6UXW23996M

Background: Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.

Indication: Cyclophosphamide is indicated for the treatment of malignant lymphomas, multiple myeloma, leukemias, mycosis fungoides (advanced disease), neuroblastoma (disseminated disease), adenocarcinoma of the ovary, retinoblastoma, and carcinoma of the breast. It is also indicated for the treatment of biopsy-proven minimal change nephrotic syndrome in pediatric patients.

Associated Conditions: Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Acute monocytic leukemia, Adenocarcinoma of the Ovaries, Breast Cancer, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia (CML), Hodgkins Disease (HD), Lung Cancer, Lupus, Lymphocytic Lymphomas, Lymphoma, Multiple Myeloma (MM), Multiple Sclerosis, Nephrotic syndrome with lesion of minimal change glomerulonephritis, Non-Hodgkin's Lymphoma (NHL), Retinoblastoma, Advanced Alibert-Bazin syndrome, Chronic Granulocytic Leukemias, Disseminated Neuroblastoma (NB), Histiocytic lymphoma, Mixed-cell type lymphoma

Associated Therapies: -

Clinical Trials

Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP in Newly Diagnosed High-intermediate and High Risk DLBCL Patients

Phase 3

Active, not recruiting

Conditions: Diffuse Large B-cell Lymphoma

Interventions: Drug: Tafasitamab
Drug: Lenalidomide
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Tafasitamab placebo
Drug: Vincristine
Drug: Lenalidomide placebo
Drug: Prednisone

First Posted Date: 2021-04-01

Last Posted Date: 2024-08-09

Lead Sponsor: Incyte Corporation

Target Recruit Count: 899

Registration Number: NCT04824092

Locations: 🇨🇳
Morphsys Research Site, Taoyuan, Taiwan
🇬🇧
MorphoSys Research Site, Wolverhampton, United Kingdom
🇷🇺
Morphosys research site, UFA, Russian Federation

and more 1 locations

Mesothelin-Specific T-Cells (FH-TCR-Tᴍsʟɴ) for the Treatment of Metastatic Pancreatic Ductal Adenocarcinoma

Phase 1

Active, not recruiting

Conditions: Metastatic Pancreatic Ductal Adenocarcinoma
Stage IV Pancreatic Cancer AJCC v8

Interventions: Biological: Autologous Mesothelin-specific TCR-T Cells
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Bendamustine

First Posted Date: 2021-03-22

Last Posted Date: 2024-10-28

Lead Sponsor: Fred Hutchinson Cancer Center

Target Recruit Count: 9

Registration Number: NCT04809766

Locations: 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

Testing the Addition of Duvelisib or CC-486 to the Usual Treatment for Peripheral T-Cell Lymphoma

Phase 2

Recruiting

Conditions: Angioimmunoblastic T-cell Lymphoma
Enteropathy-Associated T-Cell Lymphoma
Follicular T-Cell Lymphoma
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Monomorphic Epitheliotropic Intestinal T-Cell Lymphoma
Nodal Peripheral T-Cell Lymphoma With TFH Phenotype
Peripheral T-Cell Lymphoma, Not Otherwise Specified

Interventions: Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Vincristine
Drug: Prednisone
Drug: Etoposide
Drug: Duvelisib
Drug: Oral azacitidine

First Posted Date: 2021-03-17

Last Posted Date: 2024-12-27

Lead Sponsor: Alliance for Clinical Trials in Oncology

Target Recruit Count: 170

Registration Number: NCT04803201

Locations: 🇺🇸
Riverside Methodist Hospital, Columbus, Ohio, United States
🇺🇸
University of Virginia Cancer Center, Charlottesville, Virginia, United States
🇺🇸
Marshfield Medical Center - Minocqua, Minocqua, Wisconsin, United States

and more 76 locations

Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma

Phase 2

Recruiting

Conditions: Ann Arbor Stage III Diffuse Large B-Cell Lymphoma
Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma
Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma
High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type
T-Cell/Histiocyte-Rich Large B-Cell Lymphoma
Diffuse Large B-Cell Lymphoma Activated B-Cell Type
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements

Interventions: Procedure: Biospecimen Collection
Drug: Cyclophosphamide
Drug: Doxorubicin Hydrochloride
Drug: Oral Azacitidine
Drug: Prednisone
Other: Questionnaire Administration
Biological: Rituximab
Drug: Vincristine Sulfate

First Posted Date: 2021-03-16

Last Posted Date: 2025-01-08

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 422

Registration Number: NCT04799275

Locations: 🇺🇸
Banner University Medical Center - Tucson, Tucson, Arizona, United States
🇺🇸
University of Arizona Cancer Center-North Campus, Tucson, Arizona, United States
🇺🇸
University of Arkansas for Medical Sciences, Little Rock, Arkansas, United States

and more 169 locations

DALY II USA/ MB-CART2019.1 for DLBCL

Phase 2

Recruiting

Conditions: Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Relapsed Diffuse Large B Cell Lymphoma
High Grade B-cell Lymphoma (HGBCL)
Transformed Lymphoma
Primary Mediastinal B-cell Lymphoma (PMBCL)
Central Nervous System Lymphoma

Interventions: Biological: zamtocabtagene autoleucel (MB-CART2019.1)
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Bendamustine

First Posted Date: 2021-03-11

Last Posted Date: 2024-04-26

Lead Sponsor: Miltenyi Biomedicine GmbH

Target Recruit Count: 110

Registration Number: NCT04792489

Locations: 🇺🇸
University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸
Duke University Medical Center - Division of Hematologic Malignancies, Durham, North Carolina, United States
🇺🇸
Stanford University, Stanford, California, United States

and more 19 locations

A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax in Combination With Polatuzumab Vedotin Plus Rituximab (R) and Cyclophosphamide, Doxorubicin, Prednisone (CHP) in Participants With Untreated BCL-2 Immunohistochemistry (IHC)-Positive Diffuse Large B-Cell Lymphoma (DLBCL)

Phase 1

Terminated

Conditions: Lymphoma, Large B-Cell, Diffuse

Interventions: Drug: Venetoclax
Drug: Polatuzumab Vedotin
Drug: Rituximab
Drug: Cyclophosphamide
Drug: Doxorubicin
Drug: Prednisone

First Posted Date: 2021-03-10

Last Posted Date: 2024-07-11

Lead Sponsor: Hoffmann-La Roche

Target Recruit Count: 50

Registration Number: NCT04790903

Locations: 🇫🇷
Centre Hospitalier Régional Universitaire de Lille (CHRU) - Hôpital Claude Huriez, Lille, France
🇫🇷
CHU Montpellier - Saint ELOI, Montpellier, France
🇺🇸
Memorial Sloan-Kettering Cancer Center, New York, New York, United States

and more 17 locations

Study of KITE-222 in Participants With Relapsed/Refractory Acute Myeloid Leukemia

Phase 1

Terminated

Conditions: Acute Myeloid Leukemia

Interventions: Drug: Cyclophosphamide
Drug: Fludarabine
Biological: KITE-222

First Posted Date: 2021-03-09

Last Posted Date: 2024-06-10

Lead Sponsor: Kite, A Gilead Company

Target Recruit Count: 15

Registration Number: NCT04789408

Locations: 🇺🇸
Cleveland Clinic, Cleveland, Ohio, United States
🇫🇷
Institut Paoli-Calmettes, Marseille, France
🇺🇸
Stanford Cancer Center, Stanford, California, United States

and more 6 locations

Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab

Phase 1

Recruiting

Conditions: Fanconi Anemia

Interventions: Drug: JSP191
Device: CliniMACS Prodigy System
Biological: Depleted Stem Cell Transplant
Biological: Rabbit Anti-Thymoglobulin (rATG)
Drug: Cyclophosphamide
Drug: Fludarabine
Drug: Rituximab

First Posted Date: 2021-03-05

Last Posted Date: 2023-12-14

Lead Sponsor: Porteus, Matthew, MD

Target Recruit Count: 12

Registration Number: NCT04784052

Locations: 🇺🇸
Stanford University, Stanford, California, United States

Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies

Early Phase 1

Withdrawn

Conditions: Sickle Beta Thalassemia
Beta Thalassemia Major
Sickle Beta 0 Thalassemia
Sickle Beta Plus Thalassemia
Sickle Cell-SS Disease
Sickle Cell Disease